Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home
Arzu Ari,1 Karen Blain,2 Said Soubra,1 Nicola A Hanania3 1Department of Respiratory Care, Texas State University, Round Rock, TX, USA; 2Department of Respiratory Therapy, University of North Carolina Wilmington, Wilmington, NC, USA; 3Airways Clinical Research Center, Baylor College of Medicine, Hous...
Main Authors: | Ari A, Blain K, Soubra S, Hanania NA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-09-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/treating-copd-patients-with-inhaled-medications-in-the-era-of-covid-19-peer-reviewed-fulltext-article-COPD |
Similar Items
-
Reply to the reply to Scientific rationale for inhaled caspofungin to treat Pneumocystis pneumonia: A therapeutic innovation likely relevant to investigate in a near future …
by: Guillaume Desoubeaux, et al.
Published: (2020-06-01) -
Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials
by: Fischer A, et al.
Published: (2009-12-01) -
Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System
by: Tomasz R. Sosnowski
Published: (2024-01-01) -
Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease
by: Niamh Woods, et al.
Published: (2020-09-01) -
Low-Frequency Intrapulmonary Percussive Ventilation Increases Aerosol Penetration in a 2-Compartment Physical Model of Fibrotic Lung Disease
by: Sandrine Le Guellec, et al.
Published: (2020-08-01)